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Bone development is extremely sensitive to alterations in thyroid status. Recently, we analyzed the skeletal
phenotypes of mice with the dominant negative resistance to thyroid hormone (RTH) mutation PV targeted
to either the thyroid hormone receptor (TR) α1 or β gene.This perspective summarizes our findings to date
and explores the wider implications for thyroid status and T3 target gene expression in individual tissues.
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Thyroid hormone and the skeleton
Thyroid hormone (T3) is a major regulator of skeletal
development. T3-actions are mainly mediated via TRα
and TRβ nuclear receptors, which are alternatively spliced
to produce multiple isoforms [Cheng, 2000].The inception
and timing of TR expression is variable and occurs in
tissue-specific patterns in utero, throughout development
and in adulthood. Thus, TR expression is regulated in a
temporo-spatial manner and, as a consequence, the ratios
of expressed TR isoforms vary between individual tissues
[Cheng, 2000; Forrest et al., 1990]. In the skeleton, TRα1
mRNA is expressed at 12-fold higher concentrations than
TRβ1 [O'Shea et al., 2003]. TRα1, TRα2 and TRβ1
mRNAs and proteins have been identified in growth plate
chondrocytes and osteoblasts at sites of endochondral
and intramembranous ossification [Ballock et al., 1999;
Robson et al., 2000; Williams et al., 1994]. However, it is
not known whether TRα and β isoforms are co-expressed
in individual bone cells or whether discrete actions will
eventually be ascribed to each isoform.
Resistance to thyroid hormone and
mouse models
RTH is an autosomal dominant condition characterized
by reduced tissue sensitivity to thyroid hormones and
disruption in the hypothalamic-pituitary-thyroid (HPT) axis
leading to elevated levels of T3 and T4 together with
inappropriately raised TSH concentrations. Affected
individuals possess dominant-negative mutant TRβ
proteins that interfere with the actions of wild-type TRs
and disrupt T3-regulated gene transcription. The clinical
features of RTH are variable and phenotypic differences
occur between families with different mutations, between
families that harbor an identical mutation, and between
individuals of one family with an identical mutation [Weiss
and Refetoff, 2000]. An example of the phenotypic
variability is the skeleton where a wide variety of
abnormalities have been described [Kvistad et al., 2004;
Weiss and Refetoff, 1996; Weiss and Refetoff, 2000].
We previously analyzed skeletal development in mice
with a PV mutation targeted to the TRβ gene [O'Shea et
al., 2003]. The PV mutation, derived from a patient with
severe RTH and an affected skeletal phenotype [Parrilla
et al., 1991], is a C-insertion at codon 448, which
produces a frameshift of the 14 amino acids at the
carboxyl-terminal of the TRβ gene [Kaneshige et al.,
2000]. The mutant protein does not bind T3, has no
transactivation activity and is a potent dominant-negative
antagonist. Heterozygous TRβPV/+ mice mirror human
RTH with circulating concentrations of T3, T4 and TSH
increased 2-, 2.5- and 2.1-fold, respectively. Homozygous
TRβPV/PV mice have very high levels of circulating T3, T4
and TSH, elevated 9-, 15- and 412-fold, respectively
[Kaneshige et al., 2000]. We demonstrated that
homozygous TRβPV/PV mice displayed advanced
endochondral and intramembranous ossification [O'Shea
et al., 2003]. The expression of fibroblast growth factor
receptor-1 (FGFR1), previously identified as a skeletal
T3-target gene [Stevens et al., 2003], was elevated in
TRβPV mice indicating increased T3 signaling in the
mutant skeleton. Heterozygous TRβPV/+ mice
demonstrated an intermediate phenotype.Taken together,
the results suggested a phenotype of skeletal
thyrotoxicosis, consistent with the hypothesis that
elevated circulating thyroid hormone levels drive the
thyrotoxic phenotype via increased stimulation of an intact
TRα1 signaling pathway in bone.
To investigate this hypothesis and determine whether
TRα1 is the predominant TR isoform in bone, we studied
mice carrying the identical mutation targeted to TRα1
[O'Shea P et al., 2005]. The mutant TRα1PV protein is
also a potent dominant-negative antagonist capable of
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interfering with the activities of wild-type TRα1 and TRβ.
The homozygous mutation was lethal and heterozygous
TRα1PV/+ mice displayed only mild thyroid failure, with
circulating T3 and T4 levels in the euthyroid range. The
observed minor increase in T3 (1.15 fold) and no change
in T4 [Kaneshige et al., 2001] was consistent with other
mice harboring dominant-negative RTH mutations in
TRα1 [Liu et al., 2003; Tinnikov et al., 2002].
Heterozygous TRα1PV/+ mice were dwarfs, exhibiting
severely delayed endochondral and intramembranous
ossification and postnatal growth retardation. In contrast
to TRβPV mice, FGFR1 expression was reduced in
TRα1PV/+ mutants, demonstrating impaired skeletal T3
signaling and skeletal hypothyroidism in TRα1PV/+ mice,
consistent with significant levels of expressed mutant
TRα1PV in bone that impairs the activities of wild-type
TRα1 and β proteins. Our studies also indicated that the
skeletal consequences of the PV mutation, when affecting
either TRα1 or TRβ, result from dysregulated local
GH/IGF-1 signaling in the growth plate, suggesting this
signaling pathway lies downstream of TRα1 during bone
development.
Thus, TRα1PV/+ mice display skeletal hypothyroidism
despite the presence of biochemical euthyroidism [O'Shea
P et al., 2005] and, in contrast, TRβPV mice have severe
RTH but a phenotype of skeletal thyrotoxicosis [O'Shea
et al., 2003]. Our studies indicate this paradox results
from the differing effects of the PV mutations at the level
of the HPT axis and in the skeleton (Figure 1). In the
hypothalamus and pituitary, TRβ is the predominant
isoform. Mutation of TRβ has been shown to produce
RTH with elevated thyroid hormone concentrations and
impaired feedback regulation of TRH and TSH. Thus,
TRβ is critical for the determination of both the set-point
of the HPT axis and the levels of circulating thyroid
hormones [Abel et al., 2001; Abel et al., 2003; Dupre et
al., 2004; Forrest et al., 1996; Gothe et al., 1999;
Guissouma et al., 1998; Kaneshige et al., 2000]. In
TRα0/0β-/- mice, TSH elevation is more severe than in
TRβ-/- animals suggesting the TRα gene may also play a
role in set-point regulation [Gauthier et al., 2001].
However, this role is likely to be compensatory and, in
the physiological setting, TRα1 is much less important in
HPT axis regulation. Indeed, mutation of the TRα locus
has been shown to amplify the regulation of TRH in the
hypothalamus but not interfere with TSH feedback
regulation, circulating T4 and T3 levels, or affect pituitary
function [Dupre et al., 2004; Gauthier et al., 2001;
Kaneshige et al., 2001; Liu et al., 2003; Tinnikov et al.,
2002]. Thus, in TRβPV mice, the pituitary displays tissue
hypothyroidism and in TRα1PV/+ animals severe growth
retardation occurs despite normal pituitary function. In
contrast, our studies establish that TRα1 is the
predominant isoform in bone [O'Shea P et al., 2005;
O'Shea et al., 2003; Stevens et al., 2003]. Thus, in PV
mutant mice, the hyperthyroid TRβPV/PV skeleton results
from increased TRα1 activity stimulated by thyrotoxic
circulating hormone levels resulting from HPT axis
dysregulation. The phenotype is less severe in TRβPV/+
heterozygous animals because peripheral hormone
concentrations are less markedly elevated. In the TRα1PV/+
skeleton, impaired TRα1 function determines the
hypothyroid skeletal phenotype observed (Figure 2).
Figure 1.  Hypothalamic-pituitary-thyroid (HPT) axis, tissue
distribution of TRs and predominant TR-isoform responsiveness of
selective T3-target tissues Serum concentrations of the thyroid
hormones (T4 and T3) are maintained by a negative feedback system
involving the hypothalamus, the pituitary and the thyroid gland. The
circulating T3 and T4 exert direct negative feedback control on both TRH
and TSH secretion, predominantly via regulation by TRβ.TSH itself inhibits
the secretion of TRH. Relative TR distribution in individual tissues is
highlighted; blue, TRβ predominant tissue; green, mixed; yellow, TRα1
predominant tissue.
Implications of skeletal observations
Phenotypic variability is a characteristic of human RTH
and it is possible this may result from a range of individual
RTH mutations that interact with genetic background
factors leading to the production of mutant TRβ proteins
with unique properties. Each mutation may affect T3
binding affinity or cofactor interactions in a specific
manner resulting in variable dysregulation of the HPT
axis and a spectrum of dominant negative activity. In the
physiological setting, the TRβ mutation may act as a
rheostat to determine the magnitude of resistance and
the relationship of TSH to T4 and T3 levels. For instance,
if an RTH mutation had a minimal effect on T3 binding
affinity, resistance to negative feedback regulation of TSH
may be overcome easily resulting in a minor change in
circulating thyroid hormone levels. In contrast, if a
mutation severely impaired T3 binding, as in the case of
PV, TSH negative feedback regulation would be abolished
and TSH levels profoundly increased irrespective of T4
and T3 levels. It is also likely that the dominant negative
properties of each RTH mutation in each target tissue,
combined with the differing TR isoform expression ratios
in individual tissues, modifies the phenotype and provides
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Figure 2.  Proposed mechanism for TRα1PV/+ and mutant TRβPV mutant mice TRα1PV/+: In a TRβ predominant tissue, e.g. pituitary, the low levels
of PV mutant receptor are unable to interfere with the actions of wild-type TRβ. In contrast, in a TRα1 predominant tissue, e.g. bone, the increased
levels of dominant negative mutant receptor interfere with the actions of the wild-type receptors and impair the expression of T3-target genes. As a
consequence, in TRα1PV/+ mutant mice, TRβ predominant tissues exhibit a euthyroid phenotype and TRα1 predominant tissues display a hypothyroid
phenotype. TRβPV/+ and TRβPV/PV: In the TRβ predominant pituitary, there is a high level of TRβ expression relative to TRα1. Consequently, there are
increasing levels of mutant and either low levels or no wild type TRβ in TRβPV/+ and TRβPV/PV tissues, respectively. In TRα1 predominant bone, the
situation differs because levels of TRβ are low compared to TRα1. In both TRβPV/+ and TRβPV/PV mice, the low levels of mutant receptor are unable to
interfere with the action of TRα1. Thus, in TRβPV mice, where the TRβ mutant acts as a rheostat and disrupts HPT axis regulation, TRβ predominant
tissues display a hypothyroid phenotype with impaired expression of T3-target genes. TRα1 predominant tissues appear hyperthyroid in response to
increased TRα1 activity that is stimulated by thyrotoxic circulating hormone levels resulting from impaired HPT axis regulation. The phenotype is less
severe in TRβPV/+ heterozygous animals because peripheral hormone concentrations are less markedly elevated. A range of secondary mediators are
included that have recently been shown to be targets of T3 action [Barnard et al., 2005; Bassett et al., 2006; O'Shea P et al., 2005; Stevens et al., 2003;
Stevens et al., 2000].
a potential explanation for the heterogeneity observed in
RTH.
Our analysis of TRα1PV/+ and TRβPV mutant mice has
provided a new understanding of the complex relationship
between central pituitary thyroid status and peripheral
skeletal thyroid status that arises because the pituitary
gland is a TRβ target tissue, whereas bone is a TRα1
target organ. Numerous groups have demonstrated
differential TR isoform specific actions in individual tissues
suggesting the hypothesis that tissue-specific responses
to thyroid hormones result from differential TR expression
patterns. Thus, the liver, ear and retina have also been
identified as TRβ target tissues whilst the heart, like bone,
is a TRα1 target organ [Brent, 2000; Flamant and
Samarut, 2003]. Our studies in liver and heart from TRβPV
mice further indicated that tissue-specific expression of
TR isoforms dictates the dominant negative activity of the
mutant receptor [Zhang et al., 2002]. The new studies in
bone refine the hypothesis further and suggest the model
can be extended to analyze the relationship between
central and peripheral thyroid status in any T3-target
tissue, depending on whether the peripheral tissue in
question is predominantly responsive to TRα1 or TRβ.
Evidence from genetically modified mice supports this
contention. For example, in the heart, in which TRα1
predominates, TRβ-/- mice exhibit features of
thyrotoxicosis including tachycardia and increased
expression of the cyclic nucleotide-gated channels HCN2
and HCN4, which are cardiac T3-target genes [Gloss et
al., 2001]. In contrast, in TRα1-/- mice, features of
hypothyroidism have been reported including bradycardia
and reduced body temperature [Wikstrom et al., 1998].
Heart glucose utilization was reduced in TRα1PV/+ mice
and increased in TRβPV/PV animals and these opposite
effects on cardiac energy metabolism are consistent with
bradycardia associated with hypothyroidism and
tachycardia observed in hyperthyroidism and RTH [Esaki
et al., 2004]. In the reproductive system, sertoli cell
development is predominantly mediated through TRα1.
TRα-null mice exhibited hypothyroid features including
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increased sertoli cell number and testis weight while TRβ-/-
animals maintained normal sertoli cell responsiveness to
T3 [Holsberger et al., 2005]. In the liver, a
TRβ-predominant tissue, T3 influences cholesterol
metabolism via regulation of cholesterol 7α-hydroxylase
(CYP7A). TRβ-/- mice exhibit features of hypothyroidism
with loss of hepatic T3-responsiveness, whereas normal
CYP7A activity is observed in TRα1 deficient mice
[Gullberg et al., 2000]. These insights into TR
isoform-specific actions of T3 have important clinical
implications. Thus, development of TR isoform-specific
agonists and antagonists is likely to provide new
therapeutic options for the treatment of diseases such as
hypercholesterolemia, cardiac arrhythmias, growth
disorders and osteoporosis [Baxter et al., 2001].
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